Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement

  1. Ying Jie Ma  Is a corresponding author
  2. Jie Zhang
  3. Lihong Song
  4. Dennis V Pedersen
  5. Anna Li
  6. John D. Lambris
  7. Gregers Rom Andersen
  8. Tom Eirik Mollnes
  9. Peter Garred  Is a corresponding author
  1. Rigshospitalet/Copenhagen University, Denmark
  2. Aarhus University, Denmark
  3. University of Pennsylvania, United States
  4. University of Oslo, Norway

Abstract

Properdin stabilizes the alternative C3 convertase (C3bBb), whereas its role as pattern recognition molecule mediating complement activation is disputed for decades. Previously, we have found that soluble collectin-12 (sCL-12) synergizes complement alternative pathway (AP) activation. However, whether this observation is C3 dependent is unknown. By application of the C3-inhibitor Cp40, we found that properdin in normal human serum bound to Aspergillus fumigatus solely in a C3b dependent manner. Cp40 also prevented properdin binding when properdin-depleted serum reconstituted with purified properdin was applied, in analogy with the findings achieved by C3- depleted serum. However, when opsonized with sCL-12, properdin bound in a C3-independent manner exclusively via its tetrameric structure and directed in situ C3bBb assembly. In conclusion, a prerequisite for properdin binding and in situ C3bBb assembly was the initial docking of sCL-12. This implies a new important function of properdin in host defence bridging pattern recognition and specific AP activation.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Ying Jie Ma

    Department of Clinical Immunology, Rigshospitalet/Copenhagen University, Copenhagen, Denmark
    For correspondence
    ying.jie.ma@regionh.dk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4003-2579
  2. Jie Zhang

    Department of Clinical Immunology, Rigshospitalet/Copenhagen University, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4472-3468
  3. Lihong Song

    Department of Clinical Immunology, Rigshospitalet/Copenhagen University, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  4. Dennis V Pedersen

    Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
    Competing interests
    No competing interests declared.
  5. Anna Li

    Department of Clinical Immunology, Rigshospitalet/Copenhagen University, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  6. John D. Lambris

    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    John D. Lambris, inventor of patents (Patent Number: 9630992) and/or patent applications 426 (Application Number: 15/126,937) that describe the use of complement inhibitors for therapeutic purposes, the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (i.e., third-generation compstatins) for clinical applications, and the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (i.e., 4[1MeW]7W/POT-4/APL-1 and PEGylated derivatives)..
  7. Gregers Rom Andersen

    Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6292-3319
  8. Tom Eirik Mollnes

    Department of Immunology, University of Oslo, Oslo, Norway
    Competing interests
    No competing interests declared.
  9. Peter Garred

    Department of Clinical Immunology, Rigshospitalet/Copenhagen University, Copenhagen, Denmark
    For correspondence
    peter.garred@regionh.dk
    Competing interests
    No competing interests declared.

Funding

Kirsten og Freddy Johansens Fond (Research fund)

  • Ying Jie Ma

Novo Nordisk (Research fund)

  • Peter Garred

Købmand I Odense Johan og Hanne Weimann Født Seedorffs Legat (Research fund)

  • Ying Jie Ma

Alfred Benzon Foundation (Research fund)

  • Ying Jie Ma
  • Peter Garred

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Ma et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,152
    views
  • 160
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ying Jie Ma
  2. Jie Zhang
  3. Lihong Song
  4. Dennis V Pedersen
  5. Anna Li
  6. John D. Lambris
  7. Gregers Rom Andersen
  8. Tom Eirik Mollnes
  9. Peter Garred
(2020)
Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement
eLife 9:e60908.
https://doi.org/10.7554/eLife.60908

Share this article

https://doi.org/10.7554/eLife.60908

Further reading

    1. Immunology and Inflammation
    Denise M Monack
    Insight

    Macrophages control intracellular pathogens like Salmonella by using two caspase enzymes at different times during infection.

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Ainhoa Arbués, Sarah Schmidiger ... Damien Portevin
    Research Article

    The members of the Mycobacterium tuberculosis complex (MTBC) causing human tuberculosis comprise 10 phylogenetic lineages that differ in their geographical distribution. The human consequences of this phylogenetic diversity remain poorly understood. Here, we assessed the phenotypic properties at the host-pathogen interface of 14 clinical strains representing five major MTBC lineages. Using a human in vitro granuloma model combined with bacterial load assessment, microscopy, flow cytometry, and multiplexed-bead arrays, we observed considerable intra-lineage diversity. Yet, modern lineages were overall associated with increased growth rate and more pronounced granulomatous responses. MTBC lineages exhibited distinct propensities to accumulate triglyceride lipid droplets—a phenotype associated with dormancy—that was particularly pronounced in lineage 2 and reduced in lineage 3 strains. The most favorable granuloma responses were associated with strong CD4 and CD8 T cell activation as well as inflammatory responses mediated by CXCL9, granzyme B, and TNF. Both of which showed consistent negative correlation with bacterial proliferation across genetically distant MTBC strains of different lineages. Taken together, our data indicate that different virulence strategies and protective immune traits associate with MTBC genetic diversity at lineage and strain level.